Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 42338 | 4.37 |
09:34 ET | 4653 | 4.35 |
09:36 ET | 20163 | 4.37 |
09:38 ET | 9047 | 4.385 |
09:39 ET | 25733 | 4.37 |
09:41 ET | 3853 | 4.365 |
09:43 ET | 2679 | 4.36 |
09:45 ET | 8517 | 4.375 |
09:48 ET | 7570 | 4.375 |
09:50 ET | 7526 | 4.36 |
09:52 ET | 10412 | 4.355 |
09:54 ET | 82518 | 4.355 |
09:56 ET | 27754 | 4.34 |
09:57 ET | 4545 | 4.35 |
09:59 ET | 10675 | 4.35 |
10:01 ET | 7914 | 4.355 |
10:03 ET | 7412 | 4.35 |
10:06 ET | 9828 | 4.35 |
10:08 ET | 3800 | 4.355 |
10:10 ET | 13028 | 4.335 |
10:12 ET | 9432 | 4.325 |
10:14 ET | 7933 | 4.325 |
10:15 ET | 8313 | 4.335 |
10:17 ET | 2465 | 4.34 |
10:19 ET | 12484 | 4.35 |
10:21 ET | 5974 | 4.355 |
10:24 ET | 6464 | 4.335 |
10:26 ET | 2960 | 4.32 |
10:28 ET | 3280 | 4.32 |
10:30 ET | 19645 | 4.32 |
10:32 ET | 2011 | 4.325 |
10:33 ET | 10248 | 4.33 |
10:35 ET | 5838 | 4.335 |
10:37 ET | 24680 | 4.325 |
10:39 ET | 1444 | 4.325 |
10:42 ET | 9633 | 4.325 |
10:44 ET | 16223 | 4.335 |
10:46 ET | 1600 | 4.335 |
10:48 ET | 4840 | 4.33 |
10:50 ET | 519250 | 4.345 |
10:51 ET | 82274 | 4.32 |
10:53 ET | 12932 | 4.335 |
10:55 ET | 226710 | 4.345 |
10:57 ET | 74666 | 4.325 |
11:00 ET | 59210 | 4.325 |
11:02 ET | 32802 | 4.325 |
11:04 ET | 1248 | 4.33 |
11:06 ET | 22432 | 4.31 |
11:08 ET | 12599 | 4.315 |
11:09 ET | 24172 | 4.31 |
11:11 ET | 3324 | 4.319 |
11:13 ET | 1570 | 4.32 |
11:15 ET | 36271 | 4.305 |
11:18 ET | 116182 | 4.2899 |
11:20 ET | 23869 | 4.28 |
11:22 ET | 28169 | 4.275 |
11:24 ET | 36716 | 4.275 |
11:26 ET | 14579 | 4.285 |
11:27 ET | 12550 | 4.28 |
11:29 ET | 48260 | 4.285 |
11:31 ET | 12472 | 4.295 |
11:33 ET | 85557 | 4.28 |
11:36 ET | 32065 | 4.295 |
11:38 ET | 22400 | 4.295 |
11:40 ET | 5753 | 4.295 |
11:42 ET | 39444 | 4.3 |
11:44 ET | 2650 | 4.305 |
11:45 ET | 5654 | 4.3 |
11:47 ET | 4712 | 4.3 |
11:49 ET | 37841 | 4.3 |
11:51 ET | 1783 | 4.305 |
11:54 ET | 16222 | 4.295 |
11:56 ET | 13366 | 4.295 |
11:58 ET | 21488 | 4.3 |
12:00 ET | 3429 | 4.295 |
12:02 ET | 8049 | 4.3007 |
12:03 ET | 2778 | 4.305 |
12:05 ET | 56142 | 4.32 |
12:07 ET | 4766 | 4.32 |
12:09 ET | 129031 | 4.315 |
12:12 ET | 31525 | 4.325 |
12:14 ET | 19223 | 4.32 |
12:16 ET | 86002 | 4.33 |
12:18 ET | 19320 | 4.32 |
12:20 ET | 3741 | 4.325 |
12:21 ET | 1100 | 4.32 |
12:23 ET | 20470 | 4.33 |
12:25 ET | 12331 | 4.315 |
12:27 ET | 7528 | 4.315 |
12:30 ET | 1500 | 4.315 |
12:32 ET | 2404 | 4.315 |
12:34 ET | 3982 | 4.315 |
12:36 ET | 18573 | 4.325 |
12:38 ET | 7269 | 4.325 |
12:39 ET | 9642 | 4.325 |
12:41 ET | 1688 | 4.325 |
12:43 ET | 1353 | 4.33 |
12:45 ET | 13879 | 4.33 |
12:48 ET | 8901 | 4.325 |
12:50 ET | 4483 | 4.32 |
12:52 ET | 18243 | 4.3165 |
12:54 ET | 4540 | 4.315 |
12:56 ET | 3475 | 4.32 |
12:57 ET | 21728 | 4.315 |
12:59 ET | 4402 | 4.315 |
01:01 ET | 8638 | 4.31 |
01:03 ET | 6314 | 4.315 |
01:06 ET | 3838 | 4.3135 |
01:08 ET | 3348 | 4.315 |
01:10 ET | 2065 | 4.315 |
01:12 ET | 11731 | 4.32 |
01:14 ET | 11950 | 4.325 |
01:15 ET | 3903 | 4.325 |
01:17 ET | 3257 | 4.325 |
01:19 ET | 3180 | 4.325 |
01:21 ET | 3772 | 4.325 |
01:24 ET | 4214 | 4.325 |
01:26 ET | 1607 | 4.325 |
01:28 ET | 45059 | 4.315 |
01:30 ET | 93990 | 4.31 |
01:32 ET | 3760 | 4.31 |
01:33 ET | 835 | 4.32 |
01:35 ET | 16923 | 4.315 |
01:37 ET | 10066 | 4.315 |
01:39 ET | 22529 | 4.31 |
01:42 ET | 11778 | 4.315 |
01:44 ET | 1207 | 4.315 |
01:46 ET | 1144 | 4.31 |
01:48 ET | 2399 | 4.315 |
01:50 ET | 4334 | 4.315 |
01:51 ET | 6210 | 4.3105 |
01:53 ET | 9561 | 4.31 |
01:55 ET | 8417 | 4.31 |
01:57 ET | 3864 | 4.31 |
02:00 ET | 3797 | 4.31 |
02:02 ET | 8165 | 4.305 |
02:04 ET | 3973 | 4.31 |
02:06 ET | 44748 | 4.29 |
02:08 ET | 3862 | 4.29 |
02:09 ET | 14323 | 4.29 |
02:11 ET | 5001 | 4.295 |
02:13 ET | 13748 | 4.295 |
02:15 ET | 3600 | 4.295 |
02:18 ET | 2970 | 4.295 |
02:20 ET | 5628 | 4.294 |
02:22 ET | 12656 | 4.3 |
02:24 ET | 29717 | 4.32 |
02:26 ET | 25787 | 4.325 |
02:27 ET | 27802 | 4.3297 |
02:29 ET | 2700 | 4.325 |
02:31 ET | 3917 | 4.32 |
02:33 ET | 3279 | 4.325 |
02:36 ET | 5351 | 4.325 |
02:38 ET | 22845 | 4.325 |
02:40 ET | 6282 | 4.32 |
02:42 ET | 2984 | 4.325 |
02:44 ET | 3814 | 4.325 |
02:45 ET | 2434 | 4.325 |
02:47 ET | 2092 | 4.325 |
02:49 ET | 1769 | 4.325 |
02:51 ET | 11015 | 4.33 |
02:54 ET | 9259 | 4.335 |
02:56 ET | 1937 | 4.335 |
02:58 ET | 1334 | 4.34 |
03:00 ET | 49398 | 4.335 |
03:02 ET | 2503 | 4.33 |
03:03 ET | 6940 | 4.33 |
03:05 ET | 2091 | 4.32 |
03:07 ET | 5127 | 4.32 |
03:09 ET | 32387 | 4.31 |
03:12 ET | 1819 | 4.3 |
03:14 ET | 1240 | 4.3 |
03:16 ET | 12762 | 4.305 |
03:18 ET | 2019 | 4.31 |
03:20 ET | 5868 | 4.305 |
03:21 ET | 14240 | 4.315 |
03:23 ET | 5984 | 4.315 |
03:25 ET | 6456 | 4.32 |
03:27 ET | 4293 | 4.315 |
03:30 ET | 2948 | 4.31 |
03:32 ET | 1187 | 4.315 |
03:34 ET | 17904 | 4.305 |
03:36 ET | 7160 | 4.31 |
03:38 ET | 34527 | 4.315 |
03:39 ET | 2596 | 4.315 |
03:41 ET | 4087 | 4.315 |
03:43 ET | 5874 | 4.3185 |
03:45 ET | 21759 | 4.305 |
03:48 ET | 35654 | 4.315 |
03:50 ET | 9097 | 4.315 |
03:52 ET | 5986 | 4.315 |
03:54 ET | 29346 | 4.315 |
03:56 ET | 197414 | 4.32 |
03:57 ET | 55312 | 4.325 |
03:59 ET | 636753 | 4.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.6B | -12.0x | --- |
Verona Pharma PLC | 2.5B | -20.6x | --- |
Edgewise Therapeutics Inc | 2.5B | -18.5x | --- |
Structure Therapeutics Inc | 2.4B | -19.2x | --- |
CG Oncology Inc | 2.4B | -31.4x | --- |
Immunitybio Inc | 2.4B | -3.7x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 1,892.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.